Document Detail

Metabolic agents in the management of diabetic coronary patients: a new era.
MedLine Citation:
PMID:  17561287     Owner:  NLM     Status:  MEDLINE    
Modulation of myocardial free fatty acid metabolism is the key target for metabolic interventions in patients with coronary artery disease (CAD) with diabetes mellitus (DM). Because of its beneficial effects on heart metabolism at rest and on myocardial ischemia and left ventricular function, trimetazidine should be always combined with classical anti-ischemic treatment in patients with DM with CAD. We believe that, the new metabolic agents including L-carnitine, dichloroacetate, perhexiline and etomoxir will be added into our arsenal for the battle against CAD especially in patients with DM in the near future.
Turgay Celik; Hurkan Kursaklioglu; Atila Iyisoy; Bekim Jata
Related Documents :
16917107 - Altered fibrin architecture is associated with hypofibrinolysis and premature coronary ...
14579917 - Magnetocardiography in coronary artery disease with a new system in an unshielded setting.
20387137 - Combined quantitative analysis of attenuation corrected and non-corrected myocardial pe...
20862587 - Influence of small caliber coronary arteries on the diagnostic accuracy of adenosine st...
15249807 - Syncope in acute pulmonary embolism.
1826867 - Cross-sectional area index of left ventricular myocardium as a risk factor influencing ...
Publication Detail:
Type:  Comment; Letter     Date:  2007-06-11
Journal Detail:
Title:  International journal of cardiology     Volume:  127     ISSN:  1874-1754     ISO Abbreviation:  Int. J. Cardiol.     Publication Date:  2008 Jun 
Date Detail:
Created Date:  2008-05-27     Completed Date:  2008-07-31     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8200291     Medline TA:  Int J Cardiol     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  133-4     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Carnitine / therapeutic use
Coronary Disease / complications,  drug therapy*,  physiopathology
Diabetes Mellitus / drug therapy*,  metabolism,  physiopathology
Diabetic Angiopathies / complications*
Dichloroacetate / therapeutic use
Enzyme Inhibitors / therapeutic use
Epoxy Compounds / therapeutic use
Perhexiline / therapeutic use
Trimetazidine / therapeutic use
Vasodilator Agents / therapeutic use
Vitamin B Complex / therapeutic use
Reg. No./Substance:
0/Enzyme Inhibitors; 0/Epoxy Compounds; 0/Vasodilator Agents; 12001-76-2/Vitamin B Complex; 13425-80-4/Dichloroacetate; 5011-34-7/Trimetazidine; 541-15-1/Carnitine; 6621-47-2/Perhexiline; 82258-36-4/etomoxir
Comment On:
Int J Cardiol. 2008 Jun 23;127(1):124-5   [PMID:  18199501 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Central sleep apnea is associated with blunted baroreflex sensitivity in patients with myocardial in...
Next Document:  Right coronary artery (RCA) aneurysm as a collateral circulation in sub totally occluded mid RCA ste...